ArticleHealth economics, policy, and law2021
Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride?
Article in Health economics, policy, and law, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in Pharmaceutical Reimbursement in the Netherlands.PharmacoEconomics · 2026Article
- The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era.Journal of market access & health policy · 2026Article
- How Applied Researchers Engage with Methodological Tutorials: A Three-step Test Interview Study of an R Tutorial for Trial-Based Economic Evaluation.PharmacoEconomics - open · 2026Article
- Developing a Core Outcome Set for the Evaluation of Remote Patient Monitoring Interventions Using the Sextuple Aim: Modified Delphi Study.Journal of medical Internet research · 2026Article
- The launch and diffusion of new patented medicines by therapeutic value.Health affairs scholar · 2026Article
- The role of budget impact in reimbursement decisions in The Netherlands: interviews with decision-makers and pharmaceutical industry representatives.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force.International journal of technology assessment in health care · 2025Article
- A comparative analysis of patient participation in health technology assessment systems worldwide: trends and practices.Frontiers in public health · 2025Article
- The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- Assessing medical devices: a qualitative study from the validate perspective.International journal of technology assessment in health care · 2024Article
- Best practice considerations on the assessment of robotic assisted surgical systems: results from an international consensus expert panel.International journal of technology assessment in health care · 2023Review
- An introduction to health technology assessment and health economic evaluation: an online self-learning course.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2023Review
- The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.PharmacoEconomics · 2023Article
- Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands.JAMA network open · 2023Article
- Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries.Health and quality of life outcomes · 2022Article
- Real-world evidence in health technology assessment of high-risk medical devices: Fit for purpose?Health economics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, reimbursement decisions based on health technology assessments (HTA) in the Netherlands mostly concern outpatient pharmaceuticals. The Dutch government aspires to broaden the systematic application of full HTA towards other types of health care in order to optimise the content of the basic benefit package. This paper identifies important challenges for broadening the scope of full HTA to other types of health care. Based on a description of the Dutch reimbursement decision-making process, five important characteristics of outpatient pharmaceuticals were identified, which are all relevant to the successful application of HTA: (i) closed reimbursement system, (ii) absence of alternative policy measures, (iii) existence of marketing authorisation, (iv) identifiable and accountable counterparty, and (v) product characteristics. For a selection of other types of health care, which may be subject to HTA more frequently in the future, deviations from these characteristics of outpatient pharmaceuticals are discussed. The implications of such deviations for performing HTA and the decision-making process are highlighted. It is concluded that broadening the application of HTA will require policy makers to meet both important policy-related and methodological challenges. These challenges differ per health care domain, which may inform policy makers which expansions of the current use of HTA are most feasible.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.